Myeloproliferative Neoplasms (MPNs) constitute haematologic malignancies for which no curative targeted therapies are available. Epigenetic alterations and elevated activity of the transcription factor NFE2 contribute significantly to the pathophysiology of MPNs. We have identified several epigenetic regulators as novel NFE2 target genes. To generate better tools for the identification of targeted therapies we established two novel MPN mouse models.
You are here
|1985 - 1987||Study of Biochemistry, Wellesley College, Wellesley, USA|
|1987 - 1992||Study of Genetics, Harvard University / Harvard Medical School, Cambridge, USA|
|1987 - 1992||PhD work in Genetics, Harvard Medical School, Cambridge, USA|
|1992 - 1995||Postdoctoral Fellow, Gene Center, LMU Munich and University of Freiburg|
|1995 - 1997||Senior Scientist, Institute for Biochemistry and Molecular Biology, University of Freiburg|